FDA approves drugs for breast cancer
On July 18, the U.S. Food and Drug Administration (FDA) approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal…
Web Exclusives
Oral chlorhexidine can help prevent VAP
Chlorhexidine is effective as part of oral care to prevent ventilator-associated pneumonia (VAP), according to a study in Western Journal of Nursing Research. (more…)
Eating fish may prolong life
Consumption of fish (but not fried fish) and long-chain omega-3 fatty acids is associated with lower risks of early death, according to a study…
FDA requires safety labeling changes for fluoroquinolones
On July 10, the U.S. Food and Drug Administration (FDA) announced safety labeling changes for fluoroquinolones, including stronger warnings about risks of mental health…
Increasing electronic health literacy: A three-pronged approach
Use assessment, education, and support to create informed healthcare consumers. By Meigan Robb, PhD, RN, and Teresa Shellenbarger, PhD, RN, CNE, ANEF Takeaways: Changes in…
July ANA on the Frontline
Learn about the top issues facing ANA member nurses, how ANA is working for you, and what ANA is doing to advance nursing. In…
Biological clocks in digestive organs may be reason for metabolism disruption with shift work
Biological clocks (peripheral oscillators) in the liver, gut, and pancreas may be the reason for disruption of metabolism in people who work night shifts,…
High insurance denial rates for breakthrough hepatitis drugs
Insurance denial rates for direct-acting antiviral drugs used to treat hepatitis C are high—more than 50% for those with private insurance—according to a study…
FDA approves first biosimilar to Neulasta
On June 4, the U.S. Food and Drug Administration (FDA) approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to decrease the chance of…
Clinical trial participants’ views on data sharing
Most participants in clinical trials believe the benefits of broadly sharing person-level data outweigh the risks, according to a study in The New England…
The clinical opiate withdrawal protocol in an acute-care setting
How one hospital is taking a stand against the opioid epidemic. Takeaways: Limited resources for the treatment of patients experiencing opioid withdrawal often results…
Using aromatherapy in the clinical setting: Making sense of scents
Aromatherapy is an age-old therapy designed to alter mood and physical symptoms. It has gained popularity as a safe and cost-effective complementary and alternative…
FDA approves drugs for breast cancer
On July 18, the U.S. Food and Drug Administration (FDA) approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment…
Oral chlorhexidine can help prevent VAP
Chlorhexidine is effective as part of oral care to prevent ventilator-associated pneumonia (VAP), according to a study in Western Journal of Nursing…
Eating fish may prolong life
Consumption of fish (but not fried fish) and long-chain omega-3 fatty acids is associated with lower risks of early death, according to…
FDA requires safety labeling changes for fluoroquinolones
On July 10, the U.S. Food and Drug Administration (FDA) announced safety labeling changes for fluoroquinolones, including stronger warnings about risks of…
Increasing electronic health literacy: A three-pronged approach
Use assessment, education, and support to create informed healthcare consumers. By Meigan Robb, PhD, RN, and Teresa Shellenbarger, PhD, RN, CNE, ANEF Takeaways:…
July ANA on the Frontline
Learn about the top issues facing ANA member nurses, how ANA is working for you, and what ANA is doing to advance…
Biological clocks in digestive organs may be reason for metabolism disruption with shift work
Biological clocks (peripheral oscillators) in the liver, gut, and pancreas may be the reason for disruption of metabolism in people who work…
High insurance denial rates for breakthrough hepatitis drugs
Insurance denial rates for direct-acting antiviral drugs used to treat hepatitis C are high—more than 50% for those with private insurance—according to…
FDA approves first biosimilar to Neulasta
On June 4, the U.S. Food and Drug Administration (FDA) approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to decrease the…
Clinical trial participants’ views on data sharing
Most participants in clinical trials believe the benefits of broadly sharing person-level data outweigh the risks, according to a study in The…
The clinical opiate withdrawal protocol in an acute-care setting
How one hospital is taking a stand against the opioid epidemic. Takeaways: Limited resources for the treatment of patients experiencing opioid withdrawal…
Using aromatherapy in the clinical setting: Making sense of scents
Aromatherapy is an age-old therapy designed to alter mood and physical symptoms. It has gained popularity as a safe and cost-effective complementary…